Profile data is unavailable for this security.
About the company
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
- Revenue in INR (TTM)77.82bn
- Net income in INR-333.40m
- Incorporated2020
- Employees6.30k
- LocationPiramal Pharma LtdMUMBAI 400070IndiaIND
- Phone+91 223802300
- Websitehttps://www.piramal.com/businesses/piramal-pharma/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 110.51bn | 1.03k | 287.99 | -- | 18.85 | 1.67 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 18.61bn | 3.86bn | 118.82bn | 3.55k | 30.79 | -- | 21.89 | 6.38 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
| Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 132.86bn | 947.00 | 95.38 | -- | 85.87 | 11.10 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
| Concord Biotech Ltd | 9.71bn | 3.05bn | 162.49bn | -- | 54.01 | -- | 45.31 | 16.74 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 168.29bn | 1.17k | 45.36 | -- | 40.07 | 14.41 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 176.42bn | 3.98k | 13.90 | -- | 12.17 | 4.61 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Sanofi India Ltd | 28.51bn | 6.03bn | 189.92bn | 2.17k | 31.50 | 18.71 | 29.56 | 6.66 | 261.78 | 261.78 | 1,237.97 | 440.80 | 1.51 | 2.24 | 21.86 | 13,114,540.00 | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.52 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Pfizer Ltd | 22.19bn | 5.02bn | 195.76bn | 1.70k | 38.99 | -- | 33.92 | 8.82 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
| Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 197.31bn | 14.59k | 33.44 | -- | 22.50 | 3.23 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
| Piramal Enterprises Ltd | 79.98bn | -20.16bn | 200.12bn | 12.22k | -- | -- | -- | 2.50 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
| Piramal Pharma Ltd | 77.82bn | -333.40m | 202.70bn | 6.30k | -- | -- | 29.14 | 2.60 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 233.97bn | 5.75k | 146.16 | 5.69 | 42.32 | 4.64 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Syngene International Ltd | 34.89bn | 5.10bn | 267.16bn | 6.85k | 52.50 | 6.27 | 28.55 | 7.66 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 279.12bn | 5.10k | 55.11 | -- | 43.38 | 8.25 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
| Gland Pharma Ltd | 49.12bn | 6.59bn | 282.78bn | 4.59k | 42.94 | -- | 29.82 | 5.76 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
| Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 288.26bn | 15.56k | -- | -- | -- | 2.45 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
Data as of May 09 2024. Currency figures normalised to Piramal Pharma Ltd's reporting currency: Indian Rupee INR
19.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| East Bridge Capital Management L.P.as of 31 Dec 2022 | 68.68m | 5.19% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 66.26m | 5.01% |
| The Caisse de d�p�t et placement du Qu�becas of 29 May 2023 | 43.31m | 3.27% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 20.74m | 1.57% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 16.12m | 1.22% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 15.53m | 1.17% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 8.27m | 0.63% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 7.50m | 0.57% |
| Canara Robeco Asset Management Co. Ltd.as of 15 Apr 2024 | 7.50m | 0.57% |
| Nuveen Asset Management LLCas of 29 Feb 2024 | 7.30m | 0.55% |
More ▼
Data from 31 Dec 2023 - 15 Apr 2024Source: FactSet Research Systems Inc.
